These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36988996)

  • 1. Long-term Use of Eculizumab for Prolonged Hemolysis Following a Delayed Hemolytic Transfusion Reaction in Pediatric Sickle Cell: A Case Report.
    Noda C; Sisler I
    J Pediatr Pharmacol Ther; 2022; 27(6):569-572. PubMed ID: 36988996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
    Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP
    Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-N and anti-Do
    Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW
    Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions.
    Merle NS; Boudhabhay I; Leon J; Fremeaux-Bacchi V; Roumenina LT
    Transfus Clin Biol; 2019 May; 26(2):116-124. PubMed ID: 30879901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
    Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A
    Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease.
    Narbey D; Habibi A; Chadebech P; Mekontso-Dessap A; Khellaf M; Lelièvre JD; Godeau B; Michel M; Galactéros F; Djoudi R; Bartolucci P; Pirenne F
    Am J Hematol; 2017 Dec; 92(12):1340-1348. PubMed ID: 28924974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR).
    Thonier V
    Transfus Clin Biol; 2019 May; 26(2):102-108. PubMed ID: 30885514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient.
    Mpinganzima C; Haaland A; Holm AGV; Thein SL; Tjønnfjord GE; Iversen PO
    Case Rep Hematol; 2020; 2020():2765012. PubMed ID: 32351743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we better predict delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease?
    Adkins BD; Sharma D; Eichbaum Q
    Transfus Apher Sci; 2020 Apr; 59(2):102681. PubMed ID: 31831326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed Hemolytic Transfusion Reaction in a Patient with Sickle Cell Disease: Case Report.
    Omer SA; Alaesh JS; Algadeeb KB
    Int Med Case Rep J; 2020; 13():307-311. PubMed ID: 32801941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement in Sickle Cell Disease: Are We Ready for Prime Time?
    Varelas C; Tampaki A; Sakellari I; Anagnostopoulos Α; Gavriilaki E; Vlachaki E
    J Blood Med; 2021; 12():177-187. PubMed ID: 33790681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series.
    Lapite A; Bhar S; Fasipe T
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31061. PubMed ID: 38840429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease: A Case Series.
    Alwaheed AJ; Alqatari SG; AlSulaiman AS; AlSulaiman RS
    Am J Case Rep; 2022 Jan; 23():e934681. PubMed ID: 34983921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease.
    Noizat-Pirenne F; Bachir D; Chadebech P; Michel M; Plonquet A; Lecron JC; Galactéros F; Bierling P
    Haematologica; 2007 Dec; 92(12):e132-5. PubMed ID: 18055978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell disease.
    Gerritsma J; Bongaerts V; Eckhardt C; Heijboer H; Nur E; Biemond B; van der Schoot E; Fijnvandraat K;
    Br J Haematol; 2022 Feb; 196(3):769-776. PubMed ID: 34632580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease and the Role of the Classical Complement Pathway: A Case Report.
    Hair PS; Heck TP; Carr DT; Watson KD; Price J; Krishna NK; Cunnion KM; Owen WC
    J Hematol; 2021 Feb; 10(1):18-21. PubMed ID: 33643505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing.
    Tampaki A; Gavriilaki E; Varelas C; Anagnostopoulos A; Vlachaki E
    Blood Rev; 2021 Jul; 48():100805. PubMed ID: 33504459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells.
    King KE; Shirey RS; Lankiewicz MW; Young-Ramsaran J; Ness PM
    Transfusion; 1997 Apr; 37(4):376-81. PubMed ID: 9111274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient: A Case Report.
    Saleh M; Mallipeddi VP; Ali A
    Cureus; 2020 Dec; 12(12):e12167. PubMed ID: 33489579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing antibody positive delayed hemolytic transfusion reactions in sickle cell disease: Lessons learned from a case.
    Rankin A; Webb J; Nickel RS
    Transfus Med; 2022 Oct; 32(5):433-436. PubMed ID: 35318744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.